etrolizumab rhumab biopharmaceutical drug candidate developed treatment ulcerative colitis crohns disease humanized monoclonal antibody subunit integrins etrolizumab developed engineering antibody include human igglheavy chain Îºlight chain frameworks manufactured cho phase iii studies induction maintenance therapy people ulcerative colitis according data one metaanalysis efficacy etrolizumab comparable conventional therapies infliximab less adverse events phase iii clinical trials produced mixed results october hoffmannla roche parent company genentech abandoned efforts develop etrolizumab ulcerative colitis continued development crohns disease disappointing trial results led abandoned feb immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikietrolizumab